Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Infliximab (IFX) is highly effective in inducing and maintaining remission in patients with
inflammatory bowel disease (IBD). However, a large proportion of patients will eventually
lose response to IFX. Therefore, strategies to improve the outcome of maintenance treatment
with IFX are required. Retrospective analyses suggest that adjusting IFX treatment in order
to achieve IFX trough levels (TL) above a well-defined therapeutic threshold will improve the
outcome of IFX treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)